Mirum Pharmaceuticals Q3FY26 Results: Sales rise 40%, guidance beats estimates
Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M, up 40% YoY. The company raised full-year guidance to $715M-$720M, beating estimates. Livmarli drove growth, with adult PFIC as a key driver. Operating expenses were $245M, with R&D at 50% of revenue. Cash position is ~$500M. The company plans several regulatory milestones and expects cash flow positivity next year.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised FY net product sales guidance range, supported by Q3 growth and a stated runway via cash and reduced convertible note balance, alongside a pipeline calendar that could drive future estimate revisions.
Market read
Raised guidance that beats consensus can drive near-term estimate upgrades and momentum trading, while the pipeline calendar sets expectations for subsequent catalysts.
What to watch
Convertible note repurchases reduce near-term debt, but investors may focus on whether upcoming label expansions and PSC/other submissions translate into durable revenue acceleration without further dilution.
Background
Mirum is a commercial-stage rare-disease biopharma with Livmarli as the core revenue driver and multiple upcoming regulatory milestones into 2027.
Ticker impact
Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M (+40% YoY) and raised full-year guidance to $715M-$720M, beating consensus.
Likely positive bias as the market digests the raised FY sales range and sustained growth narrative into 2027 milestones.
The article provides specific, company-issued Q3 results and an explicit full-year guidance increase above consensus, which typically drives earnings-multiple and estimate revisions.
Market effects
Reinforces investor appetite for bile-acid and rare-disease commercial-stage biopharma with credible path to cash-flow positivity.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, mostly company-specific read-through to rare-disease pharma financing and pipeline credibility.
Counterpoint
Despite sales growth, R&D remains ~50% of revenue and operating cash burn is near break-even, so the market may still discount sustainability until cash-flow inflects.
Key entities
- companyMirum Pharmaceuticals
Reported Q3FY26 net product sales growth and raised full-year guidance; outlined upcoming NDA/BLA and label expansion plans.
- productLivmarli
Generated $133M net product sales in Q3FY26, including $100M from the US, and is tied to label expansion plans.
- pipeline_programVolixibat
Planned NDA submission for PSC in H1 2027, with management citing VISTAS data support.
- pipeline_programBilobatoide
Azure 4 readout expected this quarter; BLA submission planned for H1 2027.
- pipeline_programEtebriose
Launched in October after September approval for FOP; sNDA for pediatric patients planned for H1 2027.
